Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232638 | 1.00 | ACHE (0.46) | ACHEBCHE | |
| Methyl Alcohol SCHEMBL9624379 | 0.93 | ACHE (0.42) | ACHEBCHE | |
| SCHEMBL9902394 | 0.85 | ATM (0.44) | ACHEBCHE | |
| Isoquinoline SCHEMBL5264460 | 0.82 | ACHE (0.37) | ACHEBCHE | |
| SCHEMBL13659534 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL5894087 | 0.71 | CYP2A6 (0.44) | ACHEBCHE | |
| SCHEMBL25252937 | 0.70 | CYP1A2 (0.52) | — | |
| SCHEMBL31426083 | 0.70 | CYP2A6 (0.46) | ACHE | |
| SCHEMBL31228277 | 0.70 | CYP1A2 (0.46) | ACHE | |
| SCHEMBL23088139 | 0.70 | CYP2A6 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250059209-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2025-02-20 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12129265-B2 | Therapeutic agents and uses thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2024-10-29 | — | — | US | disclosed |
| CN-111447931-B | Anticancer/antifibrotic compounds | 加利福尼亚大学董事会 | 2024-01-26 | — | — | CN | disclosed |
| EP-4185288-A1 | THERAPEUTIC AGENTS AND USES THEREOF | Ankh Life Sciences Limited (IE) | 2023-05-31 | — | — | EP | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-112574107-B | Synthesis method of atropisomeric 1-arylisoquinoline N-oxide and derivatives thereof | 浙江工业大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| CN-114423757-A | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| WO-2022019892-A1 | THERAPEUTIC AGENTS AND USES THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | ACHE 4845/4885BCHE 4228/4885 |
| US-20250059209-A1 | THERAPEUTIC AGENTS AND USES THEREOF | MCL1, RNASE1, HNMT | ACHE 663/4885BCHE 1254/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ACHE 4785/4885BCHE 3186/4885 |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ACHE 4785/4885BCHE 3186/4885 |
| US-12129265-B2 | Therapeutic agents and uses thereof | MCL1, BCL9, RNASE1 | ACHE 688/4885BCHE 1153/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ACHE 1777/4885BCHE 1601/4885 |
| US-20220033417-A1 | THERAPEUTIC AGENTS AND USES THEREOF | MCL1, BCL9, RNASE1 | ACHE 688/4885BCHE 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.